

Gouvernement du Québec

O.C. 834-98, 17 June 1998

An Act respecting prescription drug insurance
(R.S.Q., c. A-29.01)

**Basic prescription drug insurance plan
— Amendments**

Regulation to amend the Regulation respecting the
basic prescription drug insurance plan

WHEREAS under subparagraph 3 of the first paragraph of section 78 of the Act respecting prescription drug insurance (R.S.Q., c. A-29.01), the Government may, after consulting the Régie de l'assurance-maladie du Québec, make regulations to determine the cases, conditions and therapeutic indications in and for which the cost of certain medications included in the list drawn up by the Minister under section 60 is covered by the basic plan; the conditions may vary according to whether the coverage is provided by the Board or under a group insurance contract or an employee benefit plan;

WHEREAS under section 79 of the Act, such a regulation is not subject to the requirements concerning publication and date of coming into force contained in sections 8 and 17 of the Regulations Act (R.S.Q., c. R-18.1);

WHEREAS by Order in Council 1519-96 dated 4 December 1996, the Government made the Regulation respecting the basic prescription drug insurance plan;

WHEREAS it is expedient to amend the Regulation;

WHEREAS, in accordance with section 78 of the Act respecting prescription drug insurance, the Régie de l'assurance-maladie du Québec has been consulted on the amendments;

IT IS ORDERED, therefore, upon the recommendation of the Minister of Health and Social Services:

THAT the Regulation to amend the Regulation respecting the basic prescription drug insurance plan, attached to this Order in Council, be made.

MICHEL NOËL DE TILLY,
Acting Clerk of the Conseil exécutif

**Regulation to amend the Regulation
respecting the basic prescription drug
insurance plan**

An Act respecting prescription drug insurance
(R.S.Q., c. A-29.01, s. 78, 1st par., subpar. 3)

1. The Regulation respecting the basic prescription drug insurance plan is amended in the second paragraph of section 2.1:

(1) by striking out subparagraph 1;

(2) by striking out the words “stable symptomatic” and everything following the word “failure” in subparagraph 14;

(3) by inserting the following subparagraph after subparagraph 18.1:

“(18.2) SODIUM DANAPAROID: as an alternative to regular heparin or to low molecular weight heparins in patients who have or who have had thrombocytopenia induced by such heparins;”;

(4) by inserting the following subparagraph after subparagraph 21:

“(21.1) DIPIVEFRIN HYDROCHLORIDE/LEVOBUNOLOL HYDROCHLORIDE: for treatment of glaucoma where treatment with a topical beta-blocker produces insufficient control of ocular tension;”;

(5) by inserting the following subparagraph after subparagraph 29:

“(29.1) DISODIUM ETIDRONATE:

(a) for treatment of Paget’s disease;

(b) for maintenance treatment of hypercalcemia of malignant origin;”;

(6) by striking out subparagraphs 30 and 31;

(7) by inserting the words “or kidney” after the word “liver” in paragraph *b* of subparagraph 42;

* The Regulation respecting the basic prescription drug insurance plan, made by Order in Council 1519-96 dated 4 December 1996 (1996, *G.O.* 2, 4941), was last amended by the Regulation made by Order in Council 391-98 dated 25 March 1998 (1998, *G.O.* 2, 1454). For previous amendments, refer to the Tableau des modifications et Index sommaire, Éditeur officiel du Québec, 1998, updated to 1 March 1998.

(8) by striking out subparagraph 48;

(9) by substituting the words “and undergoing intensive insulin therapy” for everything the word “diabetes” in subparagraph 49;

(10) by inserting the following subparagraph after subparagraph 49:

“(49.1) INTERFERON BETA 1-A: for treatment of persons suffering from cyclic remitting multiple sclerosis who are capable of walking, even if they require assistance, and who have had 2 or more episodes of the disease within the last 2 years; the physician must provide, at the beginning of treatment and with each subsequent request, the following information: number of episodes per year, result on EDSS scale, and adjuvant treatment; the maximum initial duration of authorization is 6 months and, when submitting subsequent requests, the physician must provide evidence of a beneficial effect (absence of deterioration);”;

(11) by substituting the words “is ineffective, contraindicated or poorly tolerated” for everything following the word “tetracycline” in subparagraph 61;

(12) by striking out the words “carrying a Turner’s syndrome or” in paragraph *a* of subparagraph 82;

(13) by inserting the following paragraph after paragraph *b* of subparagraph 82:

“(c) for treatment of adults suffering from growth hormone deficiency where they meet the following criteria:

— the biochemical diagnosis of growth hormone deficiency must be confirmed by a negative response to growth hormone stimulation tests (peak < 5 ng/mL by radio-immunological measurement, or peak < 2.5 ng mL by immunometric measurement);

— in the case of adult onset, the deficiency must be secondary to hypophyseal or hypothalamic disease, surgery, radiation therapy or trauma;”;

(14) by striking out the words “carrying a Turner’s syndrome or” in paragraph *a* of subparagraph 83;

(15) by inserting the following paragraph after paragraph *b* of subparagraph 83;

“(c) for treatment of adults suffering from growth hormone deficiency where they meet the following criteria:

— the biochemical diagnosis of growth hormone deficiency must be confirmed by a negative response to growth hormone stimulation tests (peak < 5 ng/mL by radio-immunological measurement, or peak < 2.5 ng/mL by immunometric measurement);

— in the case of adult onset, the deficiency must be secondary to hypophyseal or hypothalamic disease, surgery, radiation therapy or trauma;”;

(16) by striking out subparagraph 88.

2. This Regulation comes into force on 1 July 1998.

2334

Gouvernement du Québec

O.C. 841-98, 17 June 1998

Building Act
(R.S.Q., c. B-1.1)

Guarantee plan for new residential buildings

Regulation respecting the guarantee plan for new residential buildings

WHEREAS under paragraphs 19.3 to 19.6 and 38 of section 185 and section 192 of the Building Act (R.S.Q., c. B-1.1), the Régie du bâtiment du Québec may make regulations pertaining to financial guarantees applicable to the new residential building sector;

WHEREAS at its assembly held on 12 December 1995, the Board made the Regulation respecting the guarantee plan for new residential buildings;

WHEREAS in accordance with sections 10 and 11 of the Regulations Act (R.S.Q., c. R-18.1), a draft regulation entitled “Regulation respecting the guarantee plan for new residential buildings” was published in Part 2 of the *Gazette officielle du Québec* of 17 January 1996 with a notice that it could be approved by the Government at the expiry of 45 days from that publication;

WHEREAS the comments received have been examined;

WHEREAS at its assembly held on 19 June 1997, the Board made the Regulation respecting the guarantee plan for new residential buildings, with amendments;